Dr. Agarwal’s Health Care Limited, India’s largest eye care service chain, has reported its audited consolidated financial results for the quarter and fiscal year ending March 31, 2026. The company operates a network of 288 facilities across 10 countries.
Quarterly Highlights for Q4 FY2026
As of March 31, 2026, Dr. Agarwal’s network reached 288 facilities, having added 19 new centers during the quarter, which included seven secondary and twelve primary facilities. The company performed a total of 84,962 surgeries in this quarter, marking a 23.6% year-over-year growth.
The total income for Q4 FY2026 was reported at INR 577 crores, a growth of 21.2% compared to the previous year. Revenue from operations stood at INR 564 crores, reflecting a growth of 22.6%, with revenue from operations in India amounting to INR 505 crores, a 22.1% increase year-over-year. Revenue from mature facilities was INR 420 crores, showing a significant growth of 30.5%.
In terms of revenue composition, the sale of services contributed 77.5% while sale of products accounted for 22.5%. Earnings before interest, taxes, depreciation, and amortization (EBITDA) were reported at INR 174 crores, with an 18.9% growth and EBITDA margins of 30.2%. The profit after tax was INR 50 crores, reflecting a growth of 17.4% year-over-year, with profit margins at 8.7%.
Annual Highlights for 12M FY2026
For the twelve months ending March 31, 2026, the network sustained its growth with 57 new centers added throughout the year, which included one tertiary, 29 secondary, and 27 primary facilities. The company performed a total of 323,245 surgeries in this fiscal year, representing a growth of 14.5%.
Total income for the period was INR 2,125 crores, demonstrating a year-over-year growth of 20.9%. Revenue from operations for FY2026 was reported at INR 2,080 crores, up 21.6%, while revenue from operations in India reached INR 1,871 crores, growing by 21.7%. Revenue from mature facilities amounted to INR 1,632 crores, with a remarkable growth rate of 35.3%.
The sale of services constituted 78.4% of revenue from operations, with the sale of products contributing 21.6%. The company recorded an EBITDA of INR 614 crores, reflecting a 22.2% year-over-year growth and EBITDA margins of 28.9%. Finally, the profit after tax for the twelve-month period was INR 168 crores, an increase of 52.4% compared to the previous year, with profit margins at 7.9%.
